- Home
- MYNZ vs PPBT Comparison
MYNZ vs PPBT Comparison
Compare MYNZ & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- PPBT
- Stock Information
- Founded
- MYNZ 2021
- PPBT 2010
- Country
- MYNZ Germany
- PPBT Israel
- Employees
- MYNZ N/A
- PPBT N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- MYNZ Health Care
- PPBT Health Care
- Exchange
- MYNZ Nasdaq
- PPBT Nasdaq
- Market Cap
- MYNZ 7.9M
- PPBT 7.4M
- IPO Year
- MYNZ 2021
- PPBT N/A
- Fundamental
- Price
- MYNZ $1.28
- PPBT $0.84
- Analyst Decision
- MYNZ Buy
- PPBT Strong Buy
- Analyst Count
- MYNZ 2
- PPBT 1
- Target Price
- MYNZ $14.00
- PPBT $33.00
- AVG Volume (30 Days)
- MYNZ 133.9K
- PPBT 21.7M
- Earning Date
- MYNZ 12-29-2025
- PPBT 11-06-2025
- Dividend Yield
- MYNZ N/A
- PPBT N/A
- EPS Growth
- MYNZ N/A
- PPBT N/A
- EPS
- MYNZ N/A
- PPBT N/A
- Revenue
- MYNZ $659,935.00
- PPBT N/A
- Revenue This Year
- MYNZ N/A
- PPBT N/A
- Revenue Next Year
- MYNZ $5.03
- PPBT N/A
- P/E Ratio
- MYNZ N/A
- PPBT N/A
- Revenue Growth
- MYNZ N/A
- PPBT N/A
- 52 Week Low
- MYNZ $1.21
- PPBT $0.53
- 52 Week High
- MYNZ $14.39
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- MYNZ 32.80
- PPBT 53.11
- Support Level
- MYNZ $1.43
- PPBT $0.71
- Resistance Level
- MYNZ $1.47
- PPBT $0.89
- Average True Range (ATR)
- MYNZ 0.10
- PPBT 0.12
- MACD
- MYNZ -0.02
- PPBT 0.03
- Stochastic Oscillator
- MYNZ 12.77
- PPBT 30.67
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.